CTLA4 and classic Hodgkin lymphoma: Despite CTLA-4+ lymphoid subsets being identified as key players in cHL ME in several studies, few clinical trials have evaluated the effects of the combination of anti-CTLA-4 antibody (ipilimumab) with nivolumab or nivolumab and BV [15].